Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information. We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that. . . .
→ Read full post: Is Medicine a Big Data Problem?
I am excited to announce today that Harveen Sethi has joined the CCV team as an associate. She will be working closely with Brad Webb and me. Harveen is passionate about impactful disruptive innovation, especially in shaping the next frontier of healthcare. She is particularly enthusiastic about the potential of big data analytics and technology in advancing predictive diagnostics and personalized medicine. These are sweet spots for CCV. Brad and I . . .
→ Read full post: Harveen Sethi Joins Claremont Creek Ventures as Associate
Atul J. Butte, M.D., Ph.D.
Big Data Guru and Stanford Medical School Professor Atul Butte, co-founder of Numedii had his work recently profiled in the journal SCIENCE. As the article claims, the explosion of publicly available databases housing sequences, structures, and images allows life scientists to make fundamental discoveries without ever getting their hands “wet” at the lab bench. Science . . .
→ Read full post: Numedii co-founder Atul Butte featured in Science article on “Dry Biology” research
Congratulations to our portfolio company NuMedii for a publication today in Cancer Discovery, which discusses the use of its technology by Stanford researchers to identify an antidepressant as a potential treatment for small cell lung cancer.
NuMedii is a pioneer in the future of pharmacology. As medicine becomes more personalized, every individual will get a custom treatment matched to their genetic and proteomic makeup and pathways. The old way of developing . . .
→ Read full post: Numedii discovers repurposed antidepressants have potential to treat small cell lung cancer
The Edward Snowden controversy has highlighted how much presumed private data is actually on public wires, passing through public routers — effectively in the public domain.
The truth is, privacy in our modern society is misunderstood. In fact, true privacy is ephemeral. Thomas Jefferson probably died thinking that knowledge of his sexual relations with some of his slaves was going to die with him. How could he know that two centuries later, modern genetics showed . . .
→ Read full post: The Underside of the Cloud
Congratulations to Claremont Creek portfolio company Natera on closing a $54.6 million financing round. Given Claremont Creek Venture’s involvement since the company’s earliest round of financing, we know Natera is on its way to dominating the market for noninvasive, prenatal genetic testing. The financing is just the latest recent milestone for the company. In February it announced a major agreement with Quest Diagnostics, the world’s leading diagnostic information . . .
→ Read full post: Congratulations to Natera on Completing $54.6 Million Financing to Support Expansion
The human genome evolved for us as Paleolithic cavemen, arming us to cope with leopards, communicable diseases, infections, parasites and starvation. But modern society has succeeded in taming most of those risks, and now, ironically, our biggest health challenges are largely a byproduct of our success. As we extend our lifespan, cancer and cardiac disease increase in incidence. We confront an epidemic of diabetes and obesity related diseases largely caused by overconsumption and inactivity. Our genome never evolved to benefit obese 70 year olds. Cavemen didn’t typically live past 40 and didn’t drink high-fructose corn syrup in Big Gulps. . . .
→ Read full post: The Golden Age of Healthcare Investing is Now
Congratulations to Natera—our portfolio company who is the leading innovator in prenatal genetic testing! Yesterday they announced a major deal with Quest Diagnostics (NYSE: DGX), the world’s leading diagnostic information services company. Quest Diagnostics will offer physicians access to Panorama™, the new non-invasive prenatal test developed by Natera. (Read the Quest Press Release)
Panorama uses free-floating fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with . . .
→ Read full post: Congratulations: Quest Diagnostics to offer access to Natera’s Panorama, non-invasive prenatal test
A version of this article was originally published February 21, 2011 in The Health Care Blog Follow comments on the original blog post
mHealth – otherwise known as mobile healthcare – sounds like just what the doctor ordered to help make healthcare delivery cheaper and more effective. And since the Internet today essentially resides in everybody’s pocket, we have what amounts to a last-three-feet problem. So I’m not sure mHealth is ready for primetime, . . .
→ Read full post: mHealth – Potentially Valuable, But Not Ready For Primetime
When I was in high school back in the 70’s, I remember my favorite physics teacher telling me about the difference between data and information. Data was raw, unprocessed and unlinked to any meaning. Information was what data became when it was linked to meaning. This was an important distinction that has even greater meaning today in 2011.
I also remember that data was precious, hard to find and gather, and often even hard to . . .
→ Read full post: Creating Value In A World of Big Data